Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland.

Employee Rating

3.3More
TypePublic
HQBallsbridge, IE
Founded2008
Size (employees)935 (est)-9%
Websitehorizonpharma.com
Horizon Pharma was founded in 2008 and is headquartered in Ballsbridge, IE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Horizon Pharma

Jeffrey D. Kent

Jeffrey D. Kent

Senior Vice President, Medical Affairs & Outcomes Research
Brian Beeler

Brian Beeler

Chief Compliance Officer and Vice President, Associate General Counsel
Amy Grahn

Amy Grahn

Senior Vice President, Clinical Development and Operations
Robert De Vaere

Robert De Vaere

Executive Vice President and Chief Financial Officer
Ben Bove

Ben Bove

Senior Vice President, Marketing & Commercial Analytics
Show more

Horizon Pharma Office Locations

Horizon Pharma has offices in Ballsbridge, Roswell, Reinach, Mannheim and in 2 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Mannheim, DE
13 Joseph-Meyer-Straße
Reinach, CH
17 Kägenstrasse
Chicago, US
3200 150 S Wacker Dr
Lake Forest, US
Landmark of Lake Forest 2 150 S Saunders Rd
Roswell, US
270 1000 Holcomb Woods Pkwy
Show all (6)
Report incorrect company information

Horizon Pharma Financials and Metrics

Horizon Pharma Revenue

Embed Graph
View revenue for all periods
Horizon Pharma's revenue was reported to be $1.06 b in FY, 2017
USD

Revenue (Q3, 2018)

325.3m

Gross profit (Q3, 2018)

226.3m

Gross profit margin (Q3, 2018), %

69.6%

Net income (Q3, 2018)

26.0m

EBIT (Q3, 2018)

54.2m

Market capitalization (14-Dec-2018)

3.3b

Closing stock price (14-Dec-2018)

19.9

Cash (30-Sep-2018)

807.0m
Horizon Pharma's current market capitalization is $3.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

74.0m297.0m757.0m981.1m1.1b

Revenue growth, %

301%155%30%

Cost of goods sold

14.6m76.8m219.5m393.3m546.3m

Gross profit

59.4m220.2m537.5m587.8m510.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

26.2m51.9m66.1m75.1m113.1m172.8m226.5m204.7m257.4m208.7m220.9m289.5m271.6m223.9m302.8m325.3m

Cost of goods sold

5.3m7.6m24.8m13.6m28.9m61.8m61.3m77.2m81.1m85.2m139.1m130.2m125.5m116.1m100.1m99.0m

Gross profit

20.9m44.3m41.3m61.5m84.3m111.0m165.3m127.5m176.3m123.5m81.7m159.4m146.1m107.8m202.8m226.3m

Gross profit Margin, %

80%85%62%82%74%64%73%62%68%59%37%55%54%48%67%70%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

80.5m218.8m859.6m509.1m751.4m

Accounts Receivable

16.0m78.4m210.4m305.7m367.4m

Inventories

8.7m14.4m18.4m174.8m61.7m

Current Assets

110.8m329.2m1.1b1.0b1.2b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(149.0m)(263.6m)39.5m(166.8m)(410.5m)

Depreciation and Amortization

9.3m34.0m138.3m221.8m283.4m

Inventories

(3.4m)7.2m12.2m67.6m108.4m

Accounts Payable

3.9m9.4m(8.4m)32.1m(16.5m)
USDY, 2018

Financial Leverage

4.4 x
Show all financial metrics
Report incorrect company information

Horizon Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Horizon Pharma News and Updates

Report incorrect company information

Horizon Pharma Blogs

Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018

Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018 ronryan.teano@… Wed, 10/10/2018 - 08:32 Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018 10/10/18 This releas…

Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab

-- Data presented during an oral session at the American Thyroid Association Annual Meeting -- DUBLIN --(BUSINESS WIRE)--Oct. 4, 2018-- Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye

The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry

CHICAGO --(BUSINESS WIRE)--Sep. 27, 2018-- A prospective longitudinal natural history registry designed to provide long-term data evaluating people living with cystinosis was launched today at a meeting of The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) in Chicago,

Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout

DUBLIN --(BUSINESS WIRE)--Sep. 27, 2018-- Horizon Pharma plc (Nasdaq: HZNP) enrolled the first patient in a clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) with methotrexate to sustain lower serum uric acid (sUA) levels of people living with chronic gout refractory to

Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association

-- Horizon to host an investor call on Oct. 4 following the teprotumumab data presentation -- DUBLIN --(BUSINESS WIRE)--Sep. 25, 2018-- Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of

PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List

- Horizon Pharma also formally commits to become a Pledge 1% company - DUBLIN --(BUSINESS WIRE)--Jul. 25, 2018-- Horizon Pharma plc (Nasdaq: HZNP) today announced that the company has been named to PEOPLE’s “50 Companies That Care ” list for 2018. The list will be featured in the August 6, 2018

Horizon Pharma Company Life and Culture

Report incorrect company information

Horizon Pharma Frequently Asked Questions

  • When was Horizon Pharma founded?

    Horizon Pharma was founded in 2008.

  • Who are Horizon Pharma key executives?

    Horizon Pharma's key executives are Jeffrey D. Kent, Brian Beeler and Amy Grahn.

  • How many employees does Horizon Pharma have?

    Horizon Pharma has 935 employees.

  • What is Horizon Pharma revenue?

    Latest Horizon Pharma annual revenue is $1.1 b.

  • What is Horizon Pharma revenue per employee?

    Latest Horizon Pharma revenue per employee is $1.1 m.

  • Who are Horizon Pharma competitors?

    Competitors of Horizon Pharma include STERIS, Hikma Pharmaceuticals and BioScrip.

  • Where is Horizon Pharma headquarters?

    Horizon Pharma headquarters is located at Connaught House Burlington Rd, Ballsbridge.

  • Where are Horizon Pharma offices?

    Horizon Pharma has offices in Ballsbridge, Roswell, Reinach, Mannheim and in 2 other locations.

  • How many offices does Horizon Pharma have?

    Horizon Pharma has 6 offices.